Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults. Design: At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004. Participants: A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m 2 ). Interventions: Participants were randomly assigned to receive atomoxetine (n ¼ 15) or placebo (n ¼ 15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical. Measurements: Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms. Results: Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n ¼ 12) lost more body weight over the 12-week period than the placebo (n ¼ 14) group (mean (s.e.) À3.6 (1.0) kg (À3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F 4,96 ¼ 11.9; Po0.0001). Three participants in the atomoxetine group and none in the placebo group lost X5% weight. Side effects were minimal. Conclusion: Atomoxetine demonstrated modest short-term weight loss efficacy relative to placebo in this preliminary study of obese women.
Introduction
Modest weight loss can reduce health risks associated with obesity. 1 Pharmacotherapy is a recommended treatment option for individuals with a body mass index (BMI) of at least 30, or 27 kg/m 2 when obesity-related illnesses or risks such as type 2 diabetes are present. 2 Antiobesity drugs have been demonstrated to enhance weight loss when combined with interventions aimed at modifying lifestyle. 3 As available treatments do not provide adequate benefit to a large proportion of obese individuals, there is considerable need for development of new treatments. Atomoxetine (Strattera s ) is a potent and highly selective inhibitor of presynaptic norepinephrine transporter that is marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). Noradrenergic synapses in the medial and paraventricular hypothalamus are thought to play a major role in modulating satiety and feeding behaviour. 4 It is well known that activation of sympathetic nervous system (SNS) promotes energy dissipation and weight loss, and the effects of brain peptides on energy expenditure and metabolism in the peripheral tissues are mediated via changes in autonomic outflow. 5 Moreover, decreased appetite is a commonly reported side effect of atomoxetine during treatment of patients with ADHD. 6 Atomoxetine does not have monoamine releasing effects, thus is not considered to have the abuse potential of stimulants. These observations provide the rationale for testing atomoxetine as an obesity treatment.
Methods

Experimental design and setting
This was a 12-week, randomised, double-blind, parallelgroup comparison of atomoxetine and placebo treatments. Exclusion criteria were: obesity of a known endocrine origin, such as hypothyroidism or Cushing's syndrome; serious/ unstable medical illness, such as significant cardiovascular disease, liver disease, stroke, epilepsy or cancer; diabetes mellitus, uncontrolled hypertension; untreated or uncontrolled thyroid disease; major psychiatric disorder or alcohol/ substance abuse within the past year; weight loss of greater than 4 kg in the past 2 months; history of obesity surgery or planning surgery within the next 4 months; current or recent use of weight loss medications including herbs and dietary supplements known to affect body weight; current participation in other weight loss programmes; known hypersensitivity to atomoxetine; women of childbearing potential not adhering to an acceptable form of contraception; pregnant or breast-feeding women; and individuals judged by the investigators to be inappropriate for reasons such as inability to follow instructions and study procedures.
Randomisation, medication dosing and dispensing Study participants were randomised in a 1:1 ratio to receive atomoxetine or placebo capsules. Medical centre research pharmacy dispensed the study medication under blinded conditions. Computer-based randomisation was generated using a random-number table with a block size of 6. There was no stratification by demographic characteristics. The investigators were blind to the 'blocking' method used by the pharmacy, and treatment assignment codes were not available to the investigators until all study participants completed the study and data had been entered.
The study medication was dispensed in identically designed capsules -each capsule containing either 25 mg atomoxetine or placebo. The dose escalation was as follows: one capsule (atomoxetine 25 mg or placebo) daily for the first 3 days; two capsules (atomoxetine 50 mg or placebo) daily on days 4-7; and, four capsules (atomoxetine 100 mg or placebo) daily from day 8. The entire daily dose was administered in the morning. If a participant preferred not to take all four capsules at one time, taking half of the daily dose at lunch was an option. Based on tolerability, dose escalation could be withheld or decreased. Medication compliance was overseen by comparing the number of capsules dispensed and returned.
Diet and lifestyle counselling
Participants in both groups were instructed to follow an individual diet that was calculated to reduce their energy intake by 2100 kJ/day (500 kcal/day deficit) from the maintenance level of caloric intake using the World Health Organisation equations for basal metabolic rate with adjustment for activity level. Suggested diet emphasised decreasing portions, eating a variety of foods including fruits and vegetables, and drinking eight glasses of water each day. Study participants were asked to record their dietary intake in food diaries given to them. A registered dietician reviewed food diaries and provided advice regarding diet and physical activity via 10-min individual sessions every 4 weeks.
Measurements and visits
Screening visit assessments included review of medical history, physical examination and laboratory tests. After eligibility was determined at the screening visit, participants were seen at weeks 0, 2, 4, 8 and 12. During each visit, the following assessments were performed: blood pressure, heart rate, weight, adverse effects and medication accountability. Body weight was measured on a calibrated electronic scale to the nearest 0.1 kg. Participants were weighed in a hospital gown and weighed twice for accuracy with the average of the two measurements recorded. Waist circumference, fasting plasma glucose and lipid profile were assessed at baseline (week 0) and study exit. A 29-item Hamilton Rating Scale for Depression (Ham-D 29 ) 7, 8 that included additional questions to assess atypical depressive symptoms (reference) was administered by a clinician every 4 weeks. Adverse events were gathered via spontaneous reporting by participants as well as open-ended questions. Reportable adverse effects were problems that emerged during the course of treatment, or increased in severity relative to baseline.
Atomoxetine
Measures of outcome
The primary study outcome of interest was change in body weight in kilograms from baseline to study exit using actual body weight. Additionally, we examined percent change in weight and the number of participants in each group who achieved at least 5% weight loss. Secondary outcome measures included waist circumference, heart rate, blood pressure, plasma glucose and lipids, Ham-D 29 score and frequency of adverse effects.
Sample size estimation
To calculate the sample needed for this short-duration proofof-concept trial, we conducted a power analysis for a repeated measures design. Weight change in the placebo condition was held constant while change in the atomoxetine group was assumed at 0.125% per week, that is, a 12-week placebo-subtracted total weight loss of 1.5%. Variance and covariance estimates were based on placebosubtracted weight loss observed in overweight or obese adults in ADHD trials, and assumed a standard deviation of 2.5 with a constant correlation of 0.9 among time points (i.e., a compound symmetric matrix). Power was calculated assuming an alpha level of 0.05 and using GeisserGreenhouse corrected F test. Ability to detect a significant drug-by-time interaction was estimated at 86% with no attrition, 83% with 14 participants completing in each group, 79% with 13 in each group and 75% with 12 in each group. Thus, a sample size of 30 seemed justified.
Data analysis
All randomised subjects, who had at least one postrandomisation assessment, were included in the primary analysis. Weight change during the study was assessed over five study visits using the last-observation-carried-forward (LOCF) method of imputation for missing data. Primary outcomes were analysed using 2-way repeated measures analysis of variance. Categorical outcomes were compared using Fisher's exact test. For secondary analyses, data of subjects completing all visits were analysed using 2-way repeated-measures analysis of variance or t-tests as appropriate. Adverse events were compared with Fisher's exact test.
Results
Characteristics and disposition of participants
Of the 34 individuals screened for participation, four were ineligible. The 30 remaining subjects were randomised, with 15 receiving atomoxetine and 15 receiving placebo. Nine participants -six in the atomoxetine group and three in the placebo group -withdrew early; thus, 21 of 30 completed the full 12-week treatment. Reasons for early withdrawal were: time constraints (three atomoxetine, one placebo), lost to follow-up (one atomoxetine, one placebo), adverse effect (one atomoxetine), relocation (one atomoxetine) and consent withdrawn (one placebo). The only participant that cited an adverse effect for early withdrawal reported rapid heart beat. The baseline characteristics of participants were essentially similar between treatment groups (Table 1) .
For the intention-to-treat last-observation-carried-forward (ITT-LOCF) analysis, 26 patients were included. Excluded were four subjects (three atomoxetine, one placebo) who had no post-randomisation assessments; for these participants, reasons were time constraints and lost to follow-up.
Weight loss
The curves for weight loss in kilograms over the 12-week duration for atomoxetine and placebo group are shown in Figure 1 . For the ITT-LOCF sample, the mean (s.e.) body weight changed from 96.1 (3.1) kg at baseline to 92.5 (2.9) kg at week 12 for the atomoxetine group (n ¼ 12), whereas for the placebo group (n ¼ 14), the corresponding change was 102.1 (3.1)-102.2 (3.0) kg (treatment Â time interaction: F 4,96 ¼ 11.9; Po0.0001); that is, net weight change for the atomoxetine group was À3.6 (1.0) kg (À3.7%) over the 12-week period vs 0.1 (0.4) kg (0.2%) for the placebo group. Three subjects in the atomoxetine group and none in the placebo group lost X5% weight.
For the subset of patients completing the full 12-week treatment, the mean (s.e.) absolute weight for the atomoxetine group (n ¼ 9) changed from 95.3 (3.1) kg at baseline to 91.5 (2.8) kg at week 12; for the placebo group, the corresponding change was 101.7 (3.7)-101.7 (3.5) kg (treatment Â time interaction: F 4,76 ¼ 7.9; Po0.0001). Thus, the difference between treatment groups in achieved weight loss over time remained significant (À3.8 (1.3) kg (À3.8%) vs 0.0 (0.5) kg (0.0%)). Although the treatment groups did not differ significantly in their mean bodyweights at baseline (Table 1) , we re-estimated the models with baseline weight entered as a covariate; treatment Â time interaction Atomoxetine for weight reduction in obese women KM Gadde et al remained highly significant in the ANCOVA model (F ¼ 11.8; Po0.0001). Further, we noted that baseline weight itself was a significant predictor of weight loss with heavier subjects losing significantly greater amounts of weight; thus, the greater weight loss observed in the atomoxetine group could not be explained by the baseline differences in bodyweight as this group, in fact, started with a slightly lower mean bodyweight.
Secondary efficacy and safety measures
For treatment completers in the atomoxetine group, waist circumference decreased by 3.8 cm whereas for the placebo completers, the corresponding decrease was 1.0 cm (t ¼ 2.1; Po0.04). There were no clinically significant changes in fasting plasma glucose or lipids with either treatment.
Subjects in this study had negligible depressive symptoms at study entry as measured by the Ham-D 29 ; in fact, the scores were in the 'normal' range. Only one subject had a total score higher than 7. This subject's Ham-D 29 score decreased from 11 at baseline to 6 at the final visit. None of the subjects had any significant increase in Ham-D 29 scores during the study. There were no significant differences between treatment groups with regard to changes in blood pressure and heart rate. Adverse effects that occurred in at least two subjects in either group are presented in Table 2 .
Discussion
To our knowledge, this is the first randomised controlled trial assessing weight loss efficacy of atomoxetine in the treatment of obesity. This preliminary study demonstrated that atomoxetine therapy combined with hypocaloric dietary advice produced modest, but significantly greater weight loss than dietary advice alone (difference of 3.7 kg). Notably, weight loss with atomoxetine was achieved in the absence of any counselling beyond the most simple monthly 10-min session from a dietician, a level of intervention that could be practically easily implemented in most health care settings. It might be possible to enhance the magnitude of weight loss with atomoxetine therapy when combined with a more rigorous diet and lifestyle intervention than that was used in this trial. A limitation of this study is that only women were included; thus, we do not know whether these findings are applicable to obese men. Further studies of longer duration with more participants of both sexes are needed to confirm results of this trial.
As was the case in ADHD trials, tolerability of atomoxetine was quite favourable. Thus, there may exist a potential for use of atomoxetine to augment the efficacy of other antiobesity drugs. Presented are data for the 26 participants who had at least one postrandomisation assessment. There were no statistically significant differences between treatment groups with regard to specific adverse effects.
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